Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ascletis Pharma Inc.
  6. News
  7. Summary
    1672   KYG0520K1094

ASCLETIS PHARMA INC.

(1672)
  Report
Delayed Hong Kong Stock Exchange  -  04:08 2022-09-30 am EDT
2.750 HKD   +0.73%
09/28Ascletis Pharma H1 Loss Down by 20.6%
MT
09/28Ascletis Pharma Doses First Patient in Phase 2B Trial of Hepatitis B Treatment
MT
09/27Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
 SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about ASCLETIS PHARMA INC.
09/28Ascletis Pharma H1 Loss Down by 20.6%
MT
09/28Ascletis Pharma Doses First Patient in Phase 2B Trial of Hepatitis B Treatment
MT
09/27Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC..
CI
09/19Ascletis Pharma Unit Terminates Promotion Services Deal with Shanghai Roche Pharmaceuti..
MT
09/16Ascletis Pharma Inc. and Shanghai Roche Pharmaceutical Ltd. Announce Signing of an Adde..
CI
09/15Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study o..
PR
09/15Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22
CI
08/22China Approves New Drug Application for Ascletis Pharma's COVID-19 Oral Treatment
MT
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
PR
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
CI
08/16Ascletis Pharma Doses First Patient in US Clinical Study of Primary Biliary Cholangitis..
MT
08/16Vascletis Pharma Inc. Announces First Subject Dosed in the U.S. Drug-Drug Interaction S..
CI
08/08Ascletis Pharma Doses First Patient in US Clinical Study of Solid Tumor Drug
MT
08/07Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1..
PR
08/07Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1..
CI
More most relevant news
All news about ASCLETIS PHARMA INC.
09/28Ascletis Pharma H1 Loss Down by 20.6%
MT
09/28Ascletis Pharma Doses First Patient in Phase 2B Trial of Hepatitis B Treatment
MT
09/27Ascletis Announces Dosing of the First Patient in the Phase IIb Expansion Cohort of ASC..
CI
09/19Ascletis Pharma Unit Terminates Promotion Services Deal with Shanghai Roche Pharmaceuti..
MT
09/16Ascletis Pharma Inc. and Shanghai Roche Pharmaceutical Ltd. Announce Signing of an Adde..
CI
09/15Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study o..
PR
09/15Ascletis Pharma Inc. Announces Clinical Study of PD-L1 antibody ASC22
CI
08/22China Approves New Drug Application for Ascletis Pharma's COVID-19 Oral Treatment
MT
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
PR
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
CI
More news
News in other languages on ASCLETIS PHARMA INC.
09/28La perte d'Ascletis Pharma au premier semestre a diminué de 20,6 %.
09/28Ascletis Pharma administre la dose au premier patient de l'essai de phase 2B du traitem..
09/27Ascletis annonce le dosage du premier patient de la cohorte d'expansion de phase IIb d'..
09/19L'unité pharmaceutique d'Ascletis met fin à un accord de services de promotion avec Sha..
09/16Ascletis Pharma Inc. et Shanghai Roche Pharmaceutical Ltd. annoncent la signature d'un ..
09/15Ascletis Pharma Inc. annonce l'étude clinique de l'anticorps PD-L1 ASC22
08/22La Chine approuve la demande de nouveau médicament pour le traitement oral COVID-19 d'A..
08/21Ascletis annonce l'approbation IND de l'inhibiteur oral de la RdRp ASC10 pour le COVID-..
08/16Ascletis Pharma administre la dose au premier patient de l'étude clinique américaine su..
08/16Vascletis Pharma Inc. annonce que le premier sujet a reçu une dose dans le cadre de l'é..
More news
Press releases
09/15Shanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study o..
PR
08/21Ascletis Announces IND Approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
PR
08/07Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1..
PR
08/03Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by Chi..
PR
08/03Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, ..
PR
More press releases
Upcoming event on ASCLETIS PHARMA INC.